PMID- 26221212
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20150729
LR  - 20200930
IS  - 1940-5901 (Print)
IS  - 1940-5901 (Electronic)
IS  - 1940-5901 (Linking)
VI  - 8
IP  - 5
DP  - 2015
TI  - A meta-analysis of the antitumor effect and safety of bisphosphonates in the 
      treatment of multiple myeloma.
PG  - 6743-54
AB  - BACKGROUND: The objective of this meta-analysis was to determine the 
      effectiveness and safety of bisphosphonates (BPs) for patients with multiple 
      myeloma (MM). METHODS: The study included patients with MM, who were randomly 
      allocated to receive either BPs or control. PubMed/Medline, Embase, the Cochrane 
      Database of Systematic Reviews (CDSR), and the Cochrane Central Register of 
      Controlled Trials were searched up to January 2014, and only published trials 
      were included in the analysis. There was no language restriction. The results 
      were analyzed using RevMan 5.2 software, which was provided by Cochrane 
      Collaboration. RESULTS: Six randomized controlled trials (RCTs) covering 1951 
      patients with MM were included in the analysis. The clodronate subgroup showed 
      superior progression-free survival compared to the other groups. The pooled 
      hazard ratio (HR) was 0.57 [95% confidence interval (CI) 0.33-0.99, P = 0.04]. 
      Regarding overall survival (OS), only zoledronic acid showed a clear advantage 
      (HR = 0.51, 95% CI 0.33-0.77, P = 0.002) All BPs were effective at reducing 
      skeletal-related events (SREs). The pooled risk ratios for the outcome of SREs 
      were 0.72 (95% CI: 0.62-0.84, P < 0.0001) for the clodronate subgroup, 0.66 (95% 
      CI: 0.48-0.91, P = 0.007) for the pamidronate subgroup, and 0.65 (95% CI: 
      0.46-0.91, P = 0.01) for the zoledronic acid subgroup. Several adverse events 
      (AEs) were mentioned in the included RCTs; however, the pooled results showed no 
      statistically significant differences between the BP groups and the control. 
      CONCLUSIONS: The present meta-analysis demonstrated that zoledronic acid may 
      improve the OS of patients with MM. All BPs markedly decreased SREs and were 
      tolerated well.
FAU - Wang, Xiaoxue
AU  - Wang X
AD  - Department of Hematology, The First Hospital of China Medical University Shenyang 
      110001, China.
FAU - Yan, Xiaojing
AU  - Yan X
AD  - Department of Hematology, The First Hospital of China Medical University Shenyang 
      110001, China.
FAU - Li, Yan
AU  - Li Y
AD  - Department of Hematology, The First Hospital of China Medical University Shenyang 
      110001, China.
LA  - eng
PT  - Journal Article
DEP - 20150515
PL  - United States
TA  - Int J Clin Exp Med
JT  - International journal of clinical and experimental medicine
JID - 101471010
PMC - PMC4509157
OTO - NOTNLM
OT  - Multiple myeloma
OT  - bisphosphonates
OT  - clodronate
OT  - meta-analysis
OT  - pamidronate
OT  - zoledronic acid
EDAT- 2015/07/30 06:00
MHDA- 2015/07/30 06:01
PMCR- 2015/05/15
CRDT- 2015/07/30 06:00
PHST- 2015/03/04 00:00 [received]
PHST- 2015/04/30 00:00 [accepted]
PHST- 2015/07/30 06:00 [entrez]
PHST- 2015/07/30 06:00 [pubmed]
PHST- 2015/07/30 06:01 [medline]
PHST- 2015/05/15 00:00 [pmc-release]
PST - epublish
SO  - Int J Clin Exp Med. 2015 May 15;8(5):6743-54. eCollection 2015.